Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
About this trial
This is an interventional treatment trial for Multiple Sclerosis, Relapsing-Remitting focused on measuring Multiple Sclerosis, MS
Eligibility Criteria
Inclusion Criteria: Diagnosis of MS as defined by McDonald et al, criteria, # 1- 4 Between the ages of 18 and 55, inclusive Baseline EDSS score between 0.0 and 5.0, inclusive Have been treated with Avonex for at least the 12 months prior to randomization Have experienced at least one relapse (while on Avonex) within the 12 months prior to randomization. Cranial MRI scan demonstrating lesions consistent with MS. Have given written informed consent to participate in the study. Exclusion Criteria: Primary progressive, secondary progressive, or progressive relapsing MS. MS relapse has occurred within 50 days of randomization A clinically significant infectious illness within 30 days prior to randomization History of, or abnormal lab result, indicative of significant disease, that in the opinion of the investigator, would preclude the administration of a recombinant humanized antibody immunomodulating agent or Avonex for 116 weeks. History of severe allergic or anaphylactic reactions or known drug hypersensitivity. Unable to perform the Timed 25-Foot Walk, 9HPT and PASAT 3 Abnormal blood tests at Screening Visit
Sites / Locations
- University of Alabama-Birmingham, Department of Neurology
- Phoenix Neurological Associates, Ltd.
- University of Arkansas For Medical Sciences
- University of California - Irvine
- USC MS Comprehensive Care Center
- Kaiser-Permanente Medical Center
- MS Center at UCSF
- Healthsouth Rehabilitation Hospital
- University of Colorado MS Center
- Griffin Hospital
- Georgetown Univesity Hospital, Research Pharmacy
- George Washington University MS Center
- North Ridge NeuroScience Center
- Maitland Neurology
- University of Miami, Department of Neurology
- The Multiple Sclerosis Center of Atlanta
- Marietta Neurological Associates
- Northwestern University, Department of Neurology
- Rush-Presbyterian St. Luke's Medical Center
- Alexian Brothers Center for Clinical Research
- Loyola Medical Center
- Consultants in Neurology Northbrook
- Springfield Clinic Neuroscience Institute
- Indiana University Medical Center
- Mercy Hospital Outpatient Pharmacy
- LSU Neurolgoy Clinic in New Orleans
- Maine Neurology
- University of Maryland Hospital, Department of Neurology
- Brigham and Women's Hospital
- University of Massachusetts Memorial Medical Center
- Henry Ford Hospital
- Michigan State University MS Clinic
- Michigan Institute for Neurological Disorders
- Noran Neurological Clinic
- University of Mississippi Medical Center
- St. John's Mercy Medical Center
- Bernard W. Gimbel MS Center
- Upstate Clinical Research, LLC
- Albany Medical Center
- Maimonides Medical Center, Division of Neurology
- Buffalo General Hospital, Department of Neurology
- MS Care Center
- St. Luke's Roosevelt Hospital, MS Research & Treatment Center
- New York Hospital - Cornell Medical Center
- New York State Psychiatric Institution
- Strong Health Pharmacy Services
- Staten Island University Hospital
- University Hospital at Stony Brook
- SUNY Upstate Medical University
- MS Center at Carolinas Medical Center
- Raleigh Neurology Associates
- Wake Forest University School of Medicine, Department of Neurology
- Riverhills Neurology
- Cleveland Clinic Foundation
- Providence Saint Vincent Medical Center
- Geisinger Medical Center
- Hospital of the University of Pennsylvania
- Greenstein Neurology Associates & MS Institute
- Allegheny Singer Research Institute
- University of Pittsburgh, Department of Neurology
- University of Tennessee - Memphis
- Vanderbilt Medical Center
- Option Care Infusion
- UTSW Medical School
- Baylor Methodist International MS Center
- Central Texas Neurology
- Fletcher Allen Health Care
- University of Virginia Health Sciences
- Neurological Associates, Inc.
- Virginia Mason Medical Center
- MS Research Center
- St. Francis Hospital, Center for Neurological Disorders
- Universitatsklinik fur Neurologie
- Universitatsklinik fur Neurologie
- Hopital Universitaire U.L.B. Erasme
- Elisabeth Ziekenhuis
- Hopital Pellegrin Tripode, Neurologie
- Hopital neurologique Pierre Werth
- Judisches Krankenhaus
- Universitaetsklinikum Giessen, Oberarzt Neurologie
- Medizinische Hochschule Hannover, Neurologische Klinik
- Neurologische Abteilung
- Städtische Kliniken Osnabrück
- Asklepios Klinik Schildautal
- Fachbereich Neurologie und Klinische Neurophysiologie
- Hadassah Hebrew Uni Hospital, Department of Neurology
- Sheba Medical Center, MS Center
- Universita di Genova, Clinica Neurologica
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Group 1
Group 2
Adding natalizumab monthly infusion to Avonex weekly injection for up to 116 weeks.
Adding placebo monthly infusion to Avonex weekly injection for up to 116 weeks.